The average cancer drug in development is 12 years

The average cancer drug in development is 12 years, the average 510k approval with denovo is 2 years plus plus, so what would you like a development stage company for treatment to say, they moved the samples into the freezer and they will look at the stains next week and make a report about it in 3 weeks, I’d love to hear what you expect Regentys in a short 6 months to publish when as I said raise the big money once a nasdaq company since the otc is so expensive to raise money, I said that publically, should I raise 10 million at 40, 30 or even 20 percent discounts for Regentys bringing my share price to listing unreachable areas, common guys common sense!